Company / Current Liabilities
SUTRO BIOPHARMA, INC. Current Liabilities History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$75.1M
FY2025
5-year range
$41.7M / $131.9M
FY2021-FY2025
Trend
-43.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $94M to $75M over the past 2 years.
Based on SEC 10-K filings.
$75M in FY2025 with a 5-year CAGR of +20.5%.
Improved from $94M to $75M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +4.1%
- 5-Year CAGR
- +20.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +20.5%, indicating consistent growth.
- In FY2025, current liabilities decreased 43.0% year-over-year.
- Peak current liabilities was recorded in FY2024.
- Lowest current liabilities in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $75.1M | -43.0% |
| FY2024 | $131.9M | +40.7% |
| FY2023 | $93.7M | +40.9% |
| FY2022 | $66.5M | +59.4% |
| FY2021 | $41.7M | +41.0% |
| FY2020 | $29.6M | -10.2% |
| FY2019 | $33.0M | -9.5% |
| FY2018 | $36.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026